Abstract
On the basis of theoretical studies and literature data, biochemical markers of multifactorial diseases (such as presenile dementia (PD) or Alzheimer’s disease (AD), multiple sclerosis (MS), and rheumatoid arthritis (RA), reflecting the pathogenetic features of these diseases have been systematized. Amyloid β is regarded as a common marker for PD (AD) and RA (along with the BB isozyme of creatine kinase, transaminase, α and -β secretases, acetylcholine, choline acetyltransferase, and acetylcholine esterase); myelin basic protein, tumor necrosis factor α, cephalin, and linoleic acid, as markers of MS; and circulating immune complexes, rheumatoid factor (RF IgG), granzyme A, perforin, acid phosphatase, and cathepsins, as markers of RA. Their contents in biological material obtained from patients were significantly higher or lower than in similar material from healthy subjects. Changes in the levels of some markers in patients were correlated with the severity of the corresponding diseases. Arguments are presented for the possibility of nontraditional biomedical screening of potential means of “molecular biochemical treatment” of these diseases by testing biologically active compounds for these markers.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call